The Biosimilar Void

There is currently no biosimilar competition in sight for around one third of…


Interview "der Aktionär"

In an interview with "Der Aktionär", Formycon CFO Enno Spillner talks about the…


The strength of diversity

We at Formycon believe that diversity and inclusion are the fundamental pillars…


Gedeon Richter becomes strategic investor of Formycon

“Robust supply and cost-competitive manufacturing are becoming increasingly…


FYB201 achieved 38% market share in the US in December 2023

Great news from the US: Uptake of our ranibizumab biosimilar FYB201/Cimerli® in…


Formycon@JPM24

"Biosimilars literally represent a kind of democratization of innovation and…


Biosimilars - medicines of the future

What contribution can biosimilars make to reduce the burden on healthcare…


MAA Acceptance for FYB203

Another positive news at the turn of the year adds to our 2023 development…


Merry Christmas!

Time to reflect, unwind, re-energize and enjoy - we wish you and your loved…


FYB201 approved in Canada

Together with our partners Polpharma Biologics, Bioeq AG and Teva Canada, we…